No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Beacon Hospital Treats First Patient in Malaysia on Varian Halcyon System

Editor: What To Know

  • To assist in the reduction of time and construction costs from installation to first patient treatment, Halcyon offers expedited commissioning, requires less shielding than traditional systems, can fit in the majority of existing small vaults and can be installed in two weeks or less.
  • VAR) today announced a 62-year-old male with thyroid cancer was the first patient in Malaysia to be treated on the Varian Halcyon system at Beacon Hospital in Selangor.
  • “We are proud to be the first hospital in Southeast Asia equipped with the Halcyon system, and now local cancer patients no longer have to travel abroad to seek advanced cancer care,”.

Varian (NYSE: VAR) today announced a 62-year-old male with thyroid cancer was the first patient in Malaysia to be treated on the Varian Halcyon system at Beacon Hospital in Selangor.

Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity-modulated radiotherapy (IMRT), including improved patient comfort and shortening the time from installation to first-treatment without sacrificing quality. The system is well suited to treat a majority of cancer patients, offering advanced treatments for lung, prostate, breast, head & neck, and many other forms of cancer.

“We are proud to be the first hospital in Southeast Asia equipped with the Halcyon system, and now local cancer patients no longer have to travel abroad to seek advanced cancer care,” said Dato’ Dr. Ibrahim Wahid, medical director and consultant clinical oncologist at Beacon Hospital. “At Beacon Hospital, we strive to provide advanced cancer care to our patients, and we understand the anxiety and fear patients go through during treatment. The speed of treatment with Halcyon combined with the patient-focused features like the ambient lighting in the gantry opening, the integrated sound system and the couch-mounted camera, help alleviate patient concerns.”

Varian is dedicated to increasing access to advanced cancer care globally,” said Kenneth Tan, president Asia Pacific, Varian. “Halcyon was designed to deliver high-quality treatments and empower clinicians to care for more patients. It is great to see Beacon Hospital now treating patients on the system and offering these advanced treatments to patients in Malaysia.”

Halcyon features a streamlined workflow that only requires nine steps from the start to the end of treatment compared to up to more than 30 steps with older technologies. To assist in the reduction of time and construction costs from installation to first patient treatment, Halcyon offers expedited commissioning, requires less shielding than traditional systems, can fit in the majority of existing small vaults and can be installed in two weeks or less.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

VeraClinic: Pioneering Personal Transformation Through Hair Transplantation and Cosmetic Surgery in Turkey

As a testament to Turkey's legacy in the world of aesthetic medicine, VeraClinic invites you to discover the transformative power of our hair transplantation and cosmetic surgery services.

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy